KRAS and neoplasm: The studies included in this section showed the correlations between radiomic signatures and gene expression status by demonstrating the use of radiomic signature in predicting tumor morphology, distinguishing GBM phenotypes, discriminating EGFR+, EGFR− and KRAS+ tumors, and differentiating specific PDL1 subtypes.